-

Foundation Medicine Launches FoundationReport+™, a New Digital Reporting Experience to Streamline Precision Cancer Care

Innovative and interactive reporting functionality offers healthcare providers additional tools to complement integrated electronic health records and make it easier to review and act on results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced the launch of FoundationReport+, a new interactive digital report to enhance the useability of comprehensive genomic profiling (CGP) results. The digital view of the Foundation Medicine report provides physicians with an adaptable experience to view genomic insights and supports more efficient and streamlined treatment decisions for their patients.

Accessible through the Foundation Medicine online portal, the new digital reporting tool is customizable to each user’s preference and allows healthcare providers to control the depth of information they would like to see within the digital reporting experience. With improved navigation to actionable insights, the interactive functionality improves overall clarity of patients’ results compared to the traditional PDF report. In order to create an optimal user experience, FoundationReport+ will continue evolving to include new features and functionality in the months ahead based on customer feedback.

“Foundation Medicine continuously strives to deliver complex molecular information in a way that is digestible and actionable for clinicians,” says Foundation Medicine Chief Medical Officer Mia Levy, M.D. “We know that healthcare teams in the clinic are busy and looking for increased efficiency – therefore, our new digital report enables a dynamic experience to support a range of workflows and help providers more easily access targeted treatment options for their patient’s unique cancer.”

FoundationReport+’s digital reporting functionality is one of many updates Foundation Medicine is making to increase digital integration, on-the-go access, and connectivity in order to provide customers with the flexibility they need. This launch complements other recent initiatives to integrate Foundation Medicine reporting into electronic medical records with partners including Epic, OncoEMR, Cerner, and more.

“Having easily navigable access to patients’ genomic insights will help remove some of the barriers we as oncologists can face in our efforts to get individuals on the right treatments in an informed and efficient manner,” said Lee Schwartzberg, M.D., Chief of Oncology/Hematology, Renown Health-Pennington Cancer Institute. “Foundation Medicine’s solutions-oriented approach to customer service is paving the way to more accessible precision care for cancer patients.”

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

Contacts

Media:
Abigail Alderman, 781-534-3210
newsroom@foundationmedicine.com

Foundation Medicine


Release Summary
FoundationReport+ is a new interactive digital report from Foundation Medicine to enhance the useability of comprehensive genomic profiling results.
Release Versions

Contacts

Media:
Abigail Alderman, 781-534-3210
newsroom@foundationmedicine.com

Social Media Profiles
More News From Foundation Medicine

Foundation Medicine Collaborates with Sumitomo Pharma America to Advance Investigational Treatment for Patients with Acute Leukemia with NPM1 Mutations or KMT2A Rearrangements Using the FoundationOne®Heme Platform

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced a collaboration with Sumitomo Pharma America, Inc. (SMPA) to develop the FoundationOne®Heme platform as a companion diagnostic to identify patients with acute leukemia with a KMT2A rearrangement, also known as mixed lineage leukemia (MLL) rearrangement, or NPM1 mutations for potential treatment with SMPA’s enzomenib (DSP-5336), an investigational menin inhibitor. Acute l...

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine to launch two new hereditary germline tests in the United States through a partnership with Fulgent Genetics....
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.